Industry News
Pharmaceutical Industry News
Though Gilead Sciences made waves…
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting treatment for the viral infection. Now,
Viking Therapeutics and Aspen…
Viking Therapeutics and Aspen Neuroscience have both stepped up their commercialization planning, each tapping leaders with resumes spanning the likes of Amgen, Eli Lilly, Merck and GSK to oversee launch preparations for their obesity and
The FDA is apparently not charmed…
The FDA is apparently not charmed by the mischievous “Lipid Lurkers” in an Esperion Therapeutics commercial for cholesterol-lowering drug Nexlizet.
Under the agreement, Genesis is…
Under the agreement, Genesis is responsible for marketing Daiichi's 2023-approved acute myeloid leukemia med Vanflyta in 13 European countries.
Two investigational…
Two investigational cardiometabolic drugs from Eli Lilly stand out in Clarivate's annual Drugs to Watch report. Johnson & Johnson also has two drugs featured on the data analytics company's 2026 list.
Dispelling 9 Myths About Women’s Health
When it comes to heart health, immunity, reproductive health and more, misconceptions abound.
In this week’s episode of “The…
In this week’s episode of "The Top Line," Fierce Pharma’s Fraiser Kansteiner sits down with three biopharma CEOs to unpack what defined 2025 and what comes next.
Forget about Herceptin. There’s…
Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz Pharmaceuticals’ bispecific Ziihera—at least according to two experts.
Bayer has filed lawsuits against…
Bayer has filed lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual property developed three decades ago. Bayer filed separate complaints against Moderna, Johnson & Johnson and one against Pfizer and BioNTech.
M+C Saatchi North America is…
M+C Saatchi North America is turning to a longtime pharma pro to serve as its inaugural medical advisor.
All together, the top 10 spenders…
All together, the top 10 spenders shelled out $285.8 million to air their TV drug ads throughout December.
While policy shifts and leadership…
While policy shifts and leadership shakeups at institutions like the FDA dominated headlines in 2025, drugmakers would do well to sift through the noise and remain focused on what they do best—developing novel medicines to
AstraZeneca, chasing GSK’s rival…
AstraZeneca, chasing GSK's rival Benlysta, is looking to bring a subcutaneous version of its 2021-approved Saphnelo to more patients after nabbing a European nod last month.
The Centers for Disease Control…
The Centers for Disease Control and Prevention has upended the immunization schedule for children in the U.S., eliminating six of the 17 vaccines that were previously recommended to protect them from disease.
After shepherding the company…
After shepherding the company through its first approval and the successful launch of blockbuster autoimmune drug Vyvgart, argenx co-founder and chief executive Tim Van Hauwermeiren is passing the reins to the Dutch drugmaker’s operating chief.
Bausch + Lomb has partnered with…
Bausch + Lomb has partnered with the glaucoma community once again, launching its fifth annual fundraising challenge and sponsoring an awareness campaign in one of its priority therapeutic areas.
A recent survey shows that…
A recent survey shows that healthcare professionals have varied feelings on the direct-to-patient drug sales platforms increasingly launched by pharma companies—echoing patients’ own uncertainties about the services.
Regardless of the year and the…
Regardless of the year and the drug pricing landscape, the turn of the calendar always brings news of another wave of price increases. This year, pharmaceutical companies have raised the prices of more than 350
The company is planning Enhertu…
The company is planning Enhertu manufacturing expansions in the U.S., China, Japan and Germany that total $1.9 billion, Nikkei reported.
Novo Nordisk’s once-daily Wegovy…
Novo Nordisk's once-daily Wegovy pill officially debuted in the United States Monday, with the cost of the starting 1.5-mg dose set at $149 per month—or about $5 per day—for cash-paying patients. The monthly price for